239 related articles for article (PubMed ID: 18999874)
1. New strategy of antiangiogenic therapy for hepatocellular carcinoma.
Wu XZ
Neoplasma; 2008; 55(6):472-81. PubMed ID: 18999874
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma.
Wu XZ; Xie GR; Chen D
J Gastroenterol Hepatol; 2007 Aug; 22(8):1178-82. PubMed ID: 17559361
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
Pang R; Poon RT
Cancer Lett; 2006 Oct; 242(2):151-67. PubMed ID: 16564617
[TBL] [Abstract][Full Text] [Related]
4. Vascular changes in hepatocellular carcinoma.
Yang ZF; Poon RT
Anat Rec (Hoboken); 2008 Jun; 291(6):721-34. PubMed ID: 18484619
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma.
Ribatti D; Vacca A; Nico B; Sansonno D; Dammacco F
Cancer Treat Rev; 2006 Oct; 32(6):437-44. PubMed ID: 16870349
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic strategies in hepatocellular carcinoma: current status.
Zacharoulis D; Hatzitheofilou C; Athanasiou E; Zacharoulis S
Expert Rev Anticancer Ther; 2005 Aug; 5(4):645-56. PubMed ID: 16111465
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature.
Kaseb AO; Hanbali A; Cotant M; Hassan MM; Wollner I; Philip PA
Cancer; 2009 Nov; 115(21):4895-906. PubMed ID: 19637355
[TBL] [Abstract][Full Text] [Related]
8. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
9. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression.
Yoshiji H; Kuriyama S; Noguchi R; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Masaki T; Fukui H
J Hepatol; 2005 May; 42(5):687-93. PubMed ID: 15826718
[TBL] [Abstract][Full Text] [Related]
10. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis.
Noguchi R; Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Mitoro A; Tsujinoue H; Imazu H; Masaki T; Fukui H
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6038-45. PubMed ID: 14676130
[TBL] [Abstract][Full Text] [Related]
11. Targeting vessels to treat hepatocellular carcinoma.
Romanque P; Piguet AC; Dufour JF
Clin Sci (Lond); 2008 Apr; 114(7):467-77. PubMed ID: 18302534
[TBL] [Abstract][Full Text] [Related]
12. Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice.
Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y
Oncol Rep; 2005 Mar; 13(3):491-5. PubMed ID: 15706423
[TBL] [Abstract][Full Text] [Related]
13. Clinical trials of antiangiogenic therapy for hepatocellular carcinoma.
Taketomi A
Int J Clin Oncol; 2016 Apr; 21(2):213-218. PubMed ID: 26899258
[TBL] [Abstract][Full Text] [Related]
14. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma.
Liu F; Wang P; Jiang X; Tan G; Qiao H; Jiang H; Krissansen GW; Sun X
Cancer Sci; 2008 Oct; 99(10):2055-61. PubMed ID: 19016766
[TBL] [Abstract][Full Text] [Related]
15. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ
Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766
[TBL] [Abstract][Full Text] [Related]
16. Tumoral angiogenesis: review of the literature.
Khosravi Shahi P; Fernández Pineda I
Cancer Invest; 2008 Feb; 26(1):104-8. PubMed ID: 18181052
[TBL] [Abstract][Full Text] [Related]
17. [Hypoxia in hepatocellular carcinoma].
Myung SJ; Yoon JH
Korean J Hepatol; 2007 Mar; 13(1):9-19. PubMed ID: 17380070
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor.
Yoshiji H; Kuriyama S; Fukui H
Tumour Biol; 2002; 23(6):348-56. PubMed ID: 12677092
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis blockade as therapy for hepatocellular carcinoma: progress and challenges.
Hao CY
J Gastroenterol Hepatol; 2011 Jan; 26(1):4-6. PubMed ID: 21175786
[No Abstract] [Full Text] [Related]
20. Rifampicin as an oral angiogenesis inhibitor targeting hepatic cancers.
Shichiri M; Fukai N; Kono Y; Tanaka Y
Cancer Res; 2009 Jun; 69(11):4760-8. PubMed ID: 19458074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
